AstraZeneca Breast-Cancer Drug Shown to Slow Tumor Progression
June 6, 2022
(Wall Street Journal) – A new study of an AstraZeneca PLC breast-cancer drug showed it cut the risk of tumor progression by half for people with the most advanced form of the disease, offering the prospect of a new treatment for one of the most widely diagnosed cancers. AstraZeneca and Japan’s Daiichi Sankyo Co. said Enhertu, which the drugmakers developed jointly, cut disease progression in patients who took it in the study for an average of 9.9 months, compared with 5.1 months for those who were given chemotherapy. The drug also cut the risk of death by 36% compared with chemotherapy. (Read More)